Advanced search×

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.

Haematologica 95(4):613-21 (2010) PMID 20133897

Vorinostat (suberoylanilide hydroxamic acid, SAHA), an inhibitor of class I and II histone deacetylases, has been approved for the treatment of cutaneous T-cell lymphoma. In spite of emerging information on the effect of vorinostat in many types of cancer, little is yet known about this drug's mechanism of action, which is essential for its proper use in combination therapy. We investigated alterations in gene expression profile over time in cutaneous T-cell lymphoma cells treated with vorinostat. Subsequently, we evaluated inhibitors of PI3K, PIM and HSP90 as potential combination agents in the treatment of cutaneous T-cell lymphoma.

DOI: 10.3324/haematol.2009.013870
Version: za2963e q8zab q8zb5 q8zc8 q8zd7 q8zec q8zf6 q8zgb

Similar articles you may find interesting…

  1. Polycomb proteins in hematologic malignancies.

    Blood 116(25):5465-75 (2010) PMID 20716771

    We review the current understanding of the mechanisms of PcG-mediated repression and their relation to DNA methylation, and we discuss the role of the PcG system in hematopoiesis and hematologic malignancies. We suggest that alteration of different PcG members is a frequent event in leukemia and lym...
  2. Sequential combination therapy for chronic hepatitis B: more challenges to be tackled.

    Am J Gastroenterol 102(7):1544; author reply 1545 (2007) PMID 17593169

  3. Impact of hepatitis C virus infection on lifestyle.

    World J Gastroenterol 13(19):2722-6 (2007) PMID 17569142

    Of the 275 respondents, 62.2% (171) were male. Mean age was 51 (range 20-80) years. Overall, after the diagnosis of hepatitis C, 74.5% of drinkers had modified (giving up or reducing) alcohol consumption, 21.3% of smokers had modified their habits and 32.3% of subjects who reported sports activity h...